Roche Chief Says Covid Test Growth to Abate in Second Half (1)

July 22, 2021, 10:21 AM

Roche Holding AG said growth momentum for its Covid-19 testing business will probably abate in coming months, signaling a leveling off of the jackpot that fueled sales lately.

Roche’s diagnostics unit swiftly developed a wide array of tests in response to the pandemic, buoying sales and making up for a more difficult time at the pharmaceuticals division, where aging cancer medicines face competition.

The company said Thursday the test growth will probably at least slow in the second half of the year as more people get vaccinated around the world, though it won’t melt away entirely. The stock fell as ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.